. 2009 Dec 15;102(1):8–18. doi: 10.1038/sj.bjc.6605483

Table 3a. Antibody-based VEGFi and imaging biomarkers.

References	Drug, disease and trial	DCE-MRI biomarkers	N	Drug-induced changes	Prognostic and predictive values
Overmoyer et al (2004)	Docetaxel±Bevacizumab Breast cancer; Phase 2	k_ep	26	↓k_ep	NS
Wedam et al (2006)	Bevacizumab Breast cancer; Phase 2	K^trans, v_e	20	↓K^trans	NS
Jayson et al (2005)	HuMV833 (Anti-VEGF) Advanced cancer; Phase 1	K^trans k_ep rBV	20	↓k_ep	NS
Ton et al (2007)	CDP791 (Anti-VEGFR-2) Advanced Cancer; Phase 1	K^trans	31	No DCE-MRI change Dose-related volumetric change	NS

Abbreviations: VEGF=vascular endothelial growth factor; DCE-MRI=dynamic contrast-enhanced magnetic resonance imaging; k_ep=rate constant; K^trans=bi-directional transfer coefficient; rBV=regional blood volume; v_e=volume of the extravascular extracellular space (EES).